Resverlogix Corp. has announced that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix’s oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD). The Cleveland Clinic has named this trial, ASSERT, which stands for ApoA1 Synthesis Stimulation Evaluation in Patients Requiring Treatment for Coronary Artery Disease.

For the full story, Click Here

According to the findings of a recent study published in Journal of the American College of Cardiology, cardiovascular health of the obese can undergo a notable improvement if they lose some weight by eating less and undertaking more physical activity. The two-year study, conducted by researchers from Washington University School of Medicine in St Louis, found that weight loss in the obese improved some key measures of heart and vascular health.

For the Full Story, Click Here

HeartWare International Inc. took another step in its chase after one-time suitor and main competitor Thoratec Corp. filing for an investigational device exemption from the Food & Drug Administration for clearance to use its miniature heart pump in patients with end-stage heart failure who aren’t eligible for a heart transplant. The Framingham, Mass.-based device maker’s left ventricular assist device is already cleared for use as a bridge to heart transplant.

For the full story, click here

Medtronic Inc has confirmed that it had received a warning letter from U.S. health regulators calling for corrective actions based on an inspection of its Mounds View, Minnesota, facility, the headquarters of its cardiac rhythm management (CRM) business, the company’s largest unit. The letter from the Food and Drug Administration comes in the wake of problems Medtronic has had with its leads that are used with implantable cardioverter defibrillators, known as ICDs.

Boston Scientific Corporation has announced that it has received CE Mark for its PROMUS® Element(TM) Everolimus-Eluting Coronary Stent System, the Company’s third-generation drug-eluting stent (DES) technology. The PROMUS Element system incorporates a unique platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. The Company will begin marketing the PROMUS Element system immediately in the European Union and other CE Mark countries.